Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

3.6%

1 terminated/withdrawn out of 28 trials

Success Rate

95.7%

+9.2% vs industry average

Late-Stage Pipeline

36%

10 trials in Phase 3/4

Results Transparency

82%

18 of 22 completed trials have results

Key Signals

4 recruiting18 with results

Enrollment Performance

Analytics

Phase 2

12(42.9%)

Phase 3

9(32.1%)

Phase 1

6(21.4%)

Phase 4

1(3.6%)

28Total

Phase 2(12)

Phase 3(9)

Phase 1(6)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (28)

Showing 20 of 28 trials

NCT07560618Phase 4Not Yet Recruiting

Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.

Role: collaborator

NCT07453602Phase 1Recruiting

Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

Role: lead

NCT07340216Phase 1Recruiting

Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

Role: lead

NCT04845620Phase 3Completed

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

Role: lead

NCT07077902Phase 2Recruiting

A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa

Role: collaborator

NCT04804605Phase 3Completed

Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Role: lead

NCT06998056Phase 2Completed

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

Role: lead

NCT07105254Phase 2Recruiting

An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

Role: collaborator

NCT05028582Phase 3Completed

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

Role: lead

NCT04286607Phase 3Completed

Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

Role: lead

NCT04773587Phase 3Completed

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Role: lead

NCT04773600Phase 3Completed

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)

Role: lead

NCT04811131Phase 2Terminated

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

Role: lead

NCT04445987Phase 2Completed

Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Role: lead

NCT04378569Phase 1Completed

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

Role: lead

NCT04973228Phase 3Completed

Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

Role: lead

NCT04655313Phase 2Completed

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

Role: lead

NCT04156191Phase 1Completed

Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema

Role: lead

NCT04091646Phase 2Completed

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Role: lead

NCT04746911Phase 2Completed

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)

Role: lead